Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in Type I (insulin-dependent) diabetes mellitus

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Urinary growth hormone excretion in acromegaly: diagnostic value in mild disease activity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Impaired pancreatic polypeptide response to a meal in type 1 diabetic patients: vagal neuropathy or islet cell dysfunction?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Bone metabolism in obesity: changes related to severe overweight and dietary weight reduction.

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Effects of thyrotropin-releasing hormone on regional cerebral blood flow in man

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Growth hormone is assumed to be involved in the development of diabetic retinopathy. In a randomized study we evaluated the possible effects of one year treatment with a somatostatin (SRIH) analogue, octreotide, on early retinopathy and on metabolism in Type I (insulin-dependent) diabetes mellitus. Eleven patients were allocated to treatment with a continuous sc infusion of 400 micrograms octreotide per day and 9 served as controls. Only 7 patients from each group completed the study. Three octreotide-treated patients left the study owing to severe diarrhea. The subjects were evaluated at entry, after 2, 6 and 12 months treatment, and 2 months after withdrawal. Octreotide induced a decrease in GH secretion, expressed as the area under the 24 h serum GH profiles (p less than 0.05), and of the serum levels of IGF-I (p less than 0.05). The entire decline in GH levels occurred during the daytime, whereas the nocturnal levels were unaffected. Retinopathy, as assessed by determination of the blood retina barrier permeability, by colour fundus photography, and flurescein angiography was unchanged in both groups. Apart from a decline in insulin requirements, octreotide had no major effect on glycemic control, but induced a mild transient pituitary hypothyroidism, not clinically relevant. We conclude that treatment with octreotide for one year has modest effects on GH, IGF-I, and glucose metabolism, but has no significant effect on early retinopathy in Type I (insulin-dependent) diabetes.

OriginalsprogEngelsk
TidsskriftActa Endocrinologica
Vol/bind122
Udgave nummer6
Sider (fra-til)766-72
Antal sider7
ISSN0001-5598
StatusUdgivet - jun. 1990
Eksternt udgivetJa

ID: 52807105